How much funding has Maxymune Therapeutics raised?

Maxymune Therapeutics has disclosed $2.7M raised across 1 round.

Where is Maxymune Therapeutics headquartered?

Maxymune Therapeutics is headquartered in Los Altos, US.

Maxymune Therapeutics

Los Altos, US · Founded 2023 · Delaware corporation

Maxymune is a pharmaceutical company developing treatments for immunological diseases, including a small-molecule LAT1 inhibitor program targeting overactive T-cells in autoimmune conditions and an improved formulation of mycophenolic acid intended to reduce gastrointestinal side effects. Its work spans drug discovery and formulation of immunosuppressive therapies for patients with immunological disorders.

BiotechHealthtech

Founders & leadership

Tatjana NarandaNamed on SEC filing

Gordon RingoldNamed on SEC filing

Board

Neil SolomonsBoard director

Reported raises · per SEC filings

Form D private placements

$2.7M disclosed across 1 round · 2025

▶$2.7MraisedJun 2026 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Tatjana NarandaExecutive Officer, Director
Neil SolomonsDirector
Gordon RingoldExecutive Officer, Director

Offering amount: $4.5M
Amount sold: $2.7M
Minimum investment: $10K
First sale: Feb 2025
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 8

by search overlap

Primmune Therapeutics16 shared keywordsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.

Thymmune14 shared keywordsThymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.

Adaptimmune11 shared keywordsAdaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

Immunome11 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

NexImmune10 shared keywordsNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).

Georgiamune10 shared keywordsGeorgiamune is a biotechnology company developing immunotherapies and cancer vaccines, working across immuno-oncology modalities including vaccines, antibodies, small molecules, and CAR-T cells. Founded by immunotherapy pioneer Dr. Samir N. Khleif, the company focuses on translational immune therapies for cancer and immune-related diseases.

Evommune10 shared keywordsEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.

Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Maxymune Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Maxymune Therapeutics do?: Maxymune is a pharmaceutical company developing treatments for immunological diseases, including a small-molecule LAT1 inhibitor program targeting overactive T-cells in autoimmune conditions and an improved formulation of mycophenolic acid intended to reduce gastrointestinal side effects. Its work spans drug discovery and formulation of immunosuppressive therapies for patients with immunological disorders.
How much funding has Maxymune Therapeutics raised?: Maxymune Therapeutics has disclosed $2.7M raised across 1 round.
Where is Maxymune Therapeutics headquartered?: Maxymune Therapeutics is headquartered in Los Altos, US.